Discovery pharmaceutics—Challenges and opportunities
Tóm tắt
Most pharmaceutical companies are now evaluating compounds for druglike properties early in the discovery process. The data generated at these early stages allow upfront identification of potential development challenges and thus selection of the best candidates for lead nomination. Most often, lead nomination candidates are selected based on pharmacological and toxicological data. However, many drugs in development suffer from poor biopharmaceutical properties due to suboptimal physiochemical parameters. The poor biopharmaceutical properties often lead to extended timelines and a higher cost of developing the compounds. To avoid these problems and choose the best compounds from a biopharmaceutical perspective, physicochemical parameters such as solubility, lipophilicity, and stability need to be evaluated as early as possible. Furthermore, the preformulation approaches used to evaluate the compounds for their pharmacokinetic and toxicological properties need to be optimized. This minireview summarizes some of the parameters and approaches that can be used to evaluate compounds in the early stages of drug discovery.
Tài liệu tham khảo
Florence AT, Attwood D.Physicochemical Principles of Pharmacy: London, UK: Macmillan Press, 1998.
Gudmundsson OS, Venkatesh S. Strategies for in silico and experimental screening of physicochemical properties. In: Borchardt RT, Kerns EH, Lipinski CA, Thakker DR, Wang B, eds.Pharmaceutical Profiling in Drug Discovery for Lead Selection. Arlington, VA: AAPS Press; 2004;393–412.
Kerns E. High throughput physicochemical profiling for drug discovery.J Pharm Sci. 2001;90:1838–1858.
Di L, Kerns EH. Profiling drug-like properties in discovery research.Curr Opin Chem Biol. 2003;7:402–408.
Hageman MJ. Solubility, solubilization, and dissolution in drug delivery during lead optimization. AAPS Workshop, on Optimization of Drug-Like Properties During Lead Optimization; September 19–22, 2004; Parsippany, NJ.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.Adv Drug Deliv Rev. 2001;46:3–26.
Bevan CD, Lloyd RSA. High-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates.Anal Chem. 2000;72:1781–1787.
Di L, Kerns EH. Profiling drug-like properties in discovery research.Curr Opin Chem Biol. 2003;7:402–408.
Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals?Pharm Res. 2000;17:397–404.
Pudipeddi M, Serajuddin ATM. Trends in solubility of polymorphs.J Pharm Sci. 2005;94:929–939.
Huang LF, Tong WQ. Impact of solid state properties on developability assessment of drug candidates.Adv Drug Deliv Rev. 2004;56:321–334.
Jia Z, Ramstad T, Zhong M. Medium-throughput pKa screening of pharmaceuticals by pressure-assisted capillary electrophoresis.Electrophoresis. 2001;22:1112–1118.
Albert A, Serjeant EP.The Determination of Ionization Constants: A Laboratory Manual London: Chapman & Hall; 1984.
Comer J, Tam K. Lipophilicity profiles: theory and measurement. In: Testa B, van de Waterbeemd H, Folkers G, Guy R, eds.Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical, and Computational Strategies. Zurich, Switzerland: VCHA and Wiley-VCH; 2001:275–304.
Yamagami C. Recent advances in reversed-phase-HPLC techniques to determine lipophilicity. In: Testa B, van de Waterbeem H, Folkers G, Guy R, eds.Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical, and Computational Strategies. Zurich, Switzerland: VCHA and Wiley-VCH; 2001.
Kodavanti UP, Mehendale HM. Cationic amphiphilic drugs and phospholipid storage disorder.Pharmacol Rev. 1990;42:327–354.
Adamson AW, Gast AP.Physical Chemistry of Surfaces. New York, NY: John Wiley and Sons; 1997.
ICH.Stability Testing of New Drug Substances and Products. Geneva, Switzerland: IFPMA; 2003.
Fiese EF. General pharmaceutics—the new physical pharmacy.J Pharm Sci. 2003;92:1331–1342.
Bakshi M, Singh S. Development of validated stability-indicating assay methods—critical review.J Pharm Biomed Anal. 2002;28:1011–1040.
Shah KP, Zhou J, Lee R, et al. Automated analytical systems for drug development studies, I: a system for the determination of drug stability.J Pharm Biomed Anal. 1994;12:993–1001.
Sims JL, Roberts JK, Bateman AG, Carreira JA, Hardy MJ. An automated workstation for forced degradation of active pharmaceutical ingredients.J Pharm Sci. 2002;91:884–892.
Bakshi M, Singh S. ICH guidance in practice: establishment of inherent stability of secnidazole and development of a validated stability-indicating high-performance liquid chromatographic assay method.J Pharm Biomed Anal. 2004;36:769–775.
Byrn SR, Xu W, Newman AW. Chemical reactivity in solid-state pharmaceuticals: formulation implications.Adv Drug Deliv Rev. 2001;48:115–136.
Hovorka S, Schoneich C. Oxidative degradation of pharmaceuticals: theory, mechanisms and inhibition.J Pharm Sci. 2001;90:253–269.
Waterman KC, Adami RC, Alsante KM, et al. Stabilization of pharmaceuticals to oxidative degradation.Pharm Dev Technol. 2002;7:1–32.
Simon P, Veverka M, Oluliar J. New screening method for the determination of stability of pharmaceuticals.Int J Pharm. 2004;270:21–26.
Tonnesen HH. Formulation and stability testing of photolabile drugs.Int J Pharm. 2001;225:1–14.
Rourick RA, Volk KJ. Klohr E, Spears T, Kerns EH, Lee MS. Predictive strategy for the rapid structure elucidation of drug degradants.J Pharm Biomed Anal. 1996;14:1743–1752.
Rowe RC, Sheskey PJ, Weller PJ.Handbook of Pharmaceutical Excipients. London, UK: Pharmaceutical Press; 2003.
Sweetana S, Akers MJ. Solubility principles and practices for parenteral drug dosage form development.PDA J Pharm Sci Technol. 1996;50:330–342.
Simamora P, Pinsuwan S, Alvarez JM, Myrdal PB, Yalkowsky SH. Effect of pH on injection phlebitis.J Pharm Sci. 1995;84:520–522.
Johnson JLH, He Y, Yalkowsky SH. Prediction of precipitation-induced phlebitis: a statistical validation of an in vitro model.J Pharm Sci. 2003;92:1574–1581.